Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

(2011) Nicholas J. Robert et al.   Clinical Breast Cancer

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

(2011) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer

(2011) Thomas Powles et al.   UROLOGIA INTERNATIONALIS

Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects

(2010) M. Kujawski et al.   CANCER RESEARCH

Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained

(2010) Jennifer S. Ko et al.   CANCER RESEARCH

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

(2010) Anamika Bose et al.   INTERNATIONAL JOURNAL OF CANCER

An autoimmune-mediated strategy for prophylactic breast cancer vaccination

(2010) Ritika Jaini et al.   NATURE MEDICINE

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice

(2009) Yanhong Gu et al.   CLINICAL IMMUNOLOGY

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo

(2009) Cara K. Fraser et al.   EXPERIMENTAL HEMATOLOGY

Immunotherapeutic strategies in kidney cancer—when TKIs are not enough

(2009) Swethajit Biswas et al.   Nature Reviews Clinical Oncology

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo

(2008) Cara K. Fraser et al.   EXPERIMENTAL HEMATOLOGY

T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation

(2008) Sarah E Henrickson et al.   NATURE IMMUNOLOGY